This is the authors' abstract. We don't add key points for this paper.
Patients with acute myeloblastic leukemia (AML) are divided according to the French American British (FAB) classification into eight subgroups (M0 to M7) on the basis of their degree of maturation/differentiation. However, even if immunophenotypical characterization by flow cytometry is routinely used to distinguish between AML and acute lymphoblastic leukemia (ALL), it is not yet well established for the identification within the AML subgroups. Here we show that certain subgroups of AML can be identified with a good accuracy (80% of the patients we analyzed) by means of the expression of specific markers.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Pleșa et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: